NEXTBio Capital Management LP Invests $8.66 Million in Palvella Therapeutics, Inc. $PVLA

NEXTBio Capital Management LP acquired a new position in Palvella Therapeutics, Inc. (NASDAQ:PVLA) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 82,686 shares of the company’s stock, valued at approximately $8,655,000. Palvella Therapeutics accounts for 5.1% of NEXTBio Capital Management LP’s investment portfolio, making the stock its 7th biggest holding. NEXTBio Capital Management LP owned 0.70% of Palvella Therapeutics at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Aberdeen Group plc purchased a new position in shares of Palvella Therapeutics in the 3rd quarter worth about $3,212,000. First Light Asset Management LLC purchased a new position in shares of Palvella Therapeutics in the 3rd quarter worth about $33,949,000. Suvretta Capital Management LLC raised its holdings in shares of Palvella Therapeutics by 15.1% in the 3rd quarter. Suvretta Capital Management LLC now owns 822,400 shares of the company’s stock worth $51,556,000 after purchasing an additional 107,937 shares during the period. Apis Capital Advisors LLC purchased a new stake in shares of Palvella Therapeutics during the 3rd quarter valued at about $627,000. Finally, Jennison Associates LLC raised its holdings in shares of Palvella Therapeutics by 262.4% during the 4th quarter. Jennison Associates LLC now owns 387,483 shares of the company’s stock valued at $40,558,000 after buying an additional 280,573 shares during the period. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on PVLA. HC Wainwright raised their target price on Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Mizuho raised their target price on Palvella Therapeutics from $205.00 to $250.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Truist Financial set a $210.00 target price on Palvella Therapeutics in a report on Tuesday, February 24th. BTIG Research raised their target price on Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Finally, Chardan Capital reiterated a “buy” rating and set a $240.00 target price on shares of Palvella Therapeutics in a report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $199.53.

Insiders Place Their Bets

In other news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total value of $507,592.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 20.50% of the stock is currently owned by company insiders.

Palvella Therapeutics Stock Up 2.3%

Shares of NASDAQ PVLA opened at $108.81 on Friday. Palvella Therapeutics, Inc. has a fifty-two week low of $20.20 and a fifty-two week high of $151.18. The business has a 50 day moving average price of $119.52 and a two-hundred day moving average price of $108.46. The firm has a market cap of $1.56 billion, a PE ratio of -26.09 and a beta of -0.15.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, analysts anticipate that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current year.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.